Filter posts

Industry Growth Factor: Biologics

Last week, EvaluatePharma released their updated sales and R&D outlook for the drug industry in their …

IP Professors: 12-Year Data Exclusivity a Win-Win for Patient Access & Biotech Innovation

David E. Adelman of the University of Texas School of Law and Christopher M. Holman …

House Energy and Commerce Committee Vote Marks Another Step Forward on Pathway to Biosimilars

House Energy and Commerce Committee Vote Marks Another Step Forward on Pathway to Biosimilars Strong …

BIO CEO: Patient Groups Join Call for Data Protection

Biomedical innovation is not only key to our industry’s future, but more importantly, continued medical …

For July 4: Let's Thank the Inventors

My hope for America this July 4? I hope, in 100 years, the response time …

Holman: Follow-on Biologics Bill Threatens Innovation By Weakening Patent Rights

Chris Holman, Professor at the University of Missouri-Kansas City School of Law and author of …